{
    "organizations": [],
    "uuid": "7fee54157e60f9c6e42fd0fdbb80e251fa703680",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sesen-bio-reports-positive-3-mth-d/brief-sesen-bio-reports-positive-3-mth-data-from-vista-trial-of-vicinium-in-high-grade-nmibc-idUSASC0A338",
    "ord_in_thread": 0,
    "title": "BRIEF-Sesen Bio Reports Positive 3-Mth Data From VISTA Trial of Vicinium in High-Grade NMIBC",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Sesen Bio Inc:\n* PHASE 3 REGISTRATION TRIAL FOR NON-MUSCLE INVASIVE BLADDER CANCER ACHIEVES 42% COMPLETE RESPONSE RATE AT THREE MONTHS IN CARCINOMA IN SITU PATIENTS\n* TO DATE, VICINIUM HAS BEEN WELL-TOLERATED IN VISTA TRIAL\n* Reports Positive, Three-Month Data From VISTA Trial of Vicinium In High-Grade NMIBC Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-22T03:33:00.000+03:00",
    "crawled": "2018-05-22T19:30:09.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "sesen",
        "bio",
        "inc",
        "phase",
        "registration",
        "trial",
        "invasive",
        "bladder",
        "cancer",
        "achieves",
        "complete",
        "response",
        "rate",
        "three",
        "month",
        "carcinoma",
        "situ",
        "patient",
        "date",
        "vicinium",
        "vista",
        "trial",
        "report",
        "positive",
        "data",
        "vista",
        "trial",
        "vicinium",
        "nmibc",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}